Long-acting clotting agent approved for form of hemophilia

The drug Alprolix has been approved by the U.S. Food and Drug Administration as the first long-acting hemophilia B clotting agent, the FDA said in a news release.

The product, formally known as "coagulation factor IX recombinant Fc Fusion protein" is the first B remedy designed to require less frequent injections than prior treatments, the FDA said. It was approved to help control and prevent bleeding episodes and to manage bleeding during surgery.

Hemophilia B is a blood-clotting disorder, primarily affecting males, caused by an abnormal Factor IX gene. Affecting some 3,300 people in the United States, it can lead to potentially deadly bleeding episodes.

Alprolix was evaluated in clinical studies involving 123 people, ages 12-71, with severe hemophilia B. No safety issues were identified during the trials, the FDA said.

The product is manufactured by Biogen Idec, located in Cambridge, Mass.


Explore further

FDA approves rixubis for prophylactic tx in hemophilia B

More information: Visit the National Hemophilia Foundation to learn more about this disorder.

Copyright © 2014 HealthDay. All rights reserved.

Citation: Long-acting clotting agent approved for form of hemophilia (2014, March 31) retrieved 17 August 2019 from https://medicalxpress.com/news/2014-03-long-acting-clotting-agent-hemophilia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more